{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Moxifloxacin+Treatment+C", "query": { "intervention": "Moxifloxacin Treatment C" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 50, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Moxifloxacin+Treatment+C&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-30T04:55:47.404Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02027454", "title": "Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "GSK1265744", "type": "DRUG" }, { "name": "GSK1265744 matching placebo", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 42, "start_date": "2014-01", "completion_date": "2014-06", "has_results": false, "last_update_posted_date": "2014-06-16", "last_synced_at": "2026-09-30T04:55:47.404Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02027454" }, { "nct_id": "NCT01913002", "title": "Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "LX4211 800 mg", "type": "DRUG" }, { "name": "LX4211 2000 mg", "type": "DRUG" }, { "name": "moxifloxacin 400 mg", "type": "DRUG" }, { "name": "LX4211 Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lexicon Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 63, "start_date": "2013-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-10-30", "last_synced_at": "2026-09-30T04:55:47.404Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01913002" }, { "nct_id": "NCT03155893", "title": "A Study to Evaluate the Cardiac Safety of a Single Dose of AL-335 Administered on a Background of Simeprevir and Odalasvir and of Repeated Doses of Odalasvir Administered Alone in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "ODV Placebo (Matching 25 mg ODV)", "type": "DRUG" }, { "name": "ODV Placebo (Matching 200 mg ODV)", "type": "DRUG" }, { "name": "ODV Placebo (Matching 125 mg ODV)", "type": "DRUG" }, { "name": "ODV Placebo (Matching 100 mg ODV)", "type": "DRUG" }, { "name": "SMV Placebo (Matching 150 mg SMV)", "type": "DRUG" }, { "name": "AL-335 Placebo (matching 1200 mg AL-335)", "type": "DRUG" }, { "name": "Moxifloxacin Placebo (matching 400 mg moxifloxacin)", "type": "DRUG" }, { "name": "ODV 25 mg", "type": "DRUG" }, { "name": "ODV 200 mg", "type": "DRUG" }, { "name": "ODV 125 mg", "type": "DRUG" }, { "name": "ODV 100 mg", "type": "DRUG" }, { "name": "SMV 150 mg", "type": "DRUG" }, { "name": "AL-335 1200 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 59, "start_date": "2017-05-12", "completion_date": "2017-10-27", "has_results": false, "last_update_posted_date": "2017-11-14", "last_synced_at": "2026-09-30T04:55:47.404Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03155893" }, { "nct_id": "NCT03613649", "title": "Thorough QT/QTC (TQT) Clinical Trial to Evaluate the Effect of Zoliflodacin on Cardiac Repolarization in Healthy Male and Female Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Electrocardiogram Repolarisation Abnormality", "Gonococcal Infection" ], "interventions": [ { "name": "AZD0914", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 72, "start_date": "2018-09-25", "completion_date": "2019-01-02", "has_results": true, "last_update_posted_date": "2020-03-27", "last_synced_at": "2026-09-30T04:55:47.404Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03613649" }, { "nct_id": "NCT02165332", "title": "A Two-part, Single-dose, Randomized Study to Evaluate the Safety of Supra-therapeutic Doses of RO7033877 and to Investigate the Effect of RO7033877 on the QTc Interval", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "Part 1: SAD RO7033877", "type": "DRUG" }, { "name": "Part 1: SAD placebo", "type": "DRUG" }, { "name": "Part 2: Treatment A, RO7033877", "type": "DRUG" }, { "name": "Part 2: Treatment B, RO7033877", "type": "DRUG" }, { "name": "Part 2: Treatment C, moxifloxacin", "type": "DRUG" }, { "name": "Part 2: Treatment D, RO7033877 and moxifloxacin placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 64, "start_date": "2014-07", "completion_date": "2014-11", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-09-30T04:55:47.404Z", "location_count": 1, "location_summary": "Lenexa, Kansas", "locations": [ { "city": "Lenexa", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02165332" }, { "nct_id": "NCT05716854", "title": "Electrophysiological Effects of Potential QT Prolonging Drugs", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug-induced QT Prolongation", "Pharmacokinetics", "Pharmacodynamics" ], "interventions": [ { "name": "Clarithromycin", "type": "DRUG" }, { "name": "Pimozide", "type": "DRUG" }, { "name": "Placebo (Part 1)", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" }, { "name": "Cobicistat", "type": "DRUG" }, { "name": "Moxifloxacin and Cobicistat", "type": "DRUG" }, { "name": "Placebo (Part 2)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Food and Drug Administration (FDA)", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 44, "start_date": "2023-03-21", "completion_date": "2023-06-13", "has_results": false, "last_update_posted_date": "2023-06-22", "last_synced_at": "2026-09-30T04:55:47.404Z", "location_count": 1, "location_summary": "West Bend, Wisconsin", "locations": [ { "city": "West Bend", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05716854" }, { "nct_id": "NCT05995444", "title": "A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Epetraborole and matching placebo", "type": "DRUG" }, { "name": "Epetraborole", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AN2 Therapeutics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 24, "start_date": "2023-06-05", "completion_date": "2023-08-03", "has_results": false, "last_update_posted_date": "2023-12-21", "last_synced_at": "2026-09-30T04:55:47.404Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05995444" }, { "nct_id": "NCT01191723", "title": "QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "MAP0004", "type": "DRUG" }, { "name": "Inhaler Placebo", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" }, { "name": "Placebo Capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Allergan", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 54, "start_date": "2010-08", "completion_date": "2010-09", "has_results": true, "last_update_posted_date": "2014-01-09", "last_synced_at": "2026-09-30T04:55:47.404Z", "location_count": 1, "location_summary": "Fargo, North Dakota", "locations": [ { "city": "Fargo", "state": "North Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01191723" }, { "nct_id": "NCT01613040", "title": "A Study of the Effect of RO4917838 on the QTcF Interval in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "Moxifloxacin", "type": "DRUG" }, { "name": "RO4917838", "type": "DRUG" }, { "name": "RO4917838 placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "MALE", "summary": "18 Years to 65 Years · Male only" }, "enrollment_count": 169, "start_date": "2009-01", "completion_date": "2009-07", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-09-30T04:55:47.404Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01613040" }, { "nct_id": "NCT00890565", "title": "Safety Study of Electrocardiogram (ECG) Effects of Sancuso® (Granisetron TDS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "granisetron", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyowa Kirin Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 240, "start_date": "2009-05", "completion_date": "2009-09", "has_results": false, "last_update_posted_date": "2024-06-17", "last_synced_at": "2026-09-30T04:55:47.404Z", "location_count": 1, "location_summary": "West Bend, Wisconsin", "locations": [ { "city": "West Bend", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00890565" } ] }